Table 1

Ongoing and emerging clinical trials in PDAC using CAR-T therapy and novel combinations with ICI

Interventions	Phases	Locations	NCT number	Status
Viral and vaccine-based therapies
Pembrolizumab\|wild-type reovirus	Phase II	Northwestern University, Chicago, Illinois, USA	NCT03723915	Ongoing
GRT-C903\|GRT-R904\|nivolumab\|ipilimumab	Phase I Phase II	Multicenter	NCT03953235	Ongoing
Cyclophosphamide\|nivolumab\|ipilimumab\|GVAX pancreas vaccine\|CRS-207	Phase II	Johns Hopkins SKCCC, Baltimore, Maryland, USA	NCT03190265	Ongoing
Cyclophosphamide\|nivolumab\|GVAX pancreas vaccine\|radiation: SBRT	Phase II	Multicenter	NCT03161379	Ongoing
Epacadostat\|pembrolizumab\|CRS-207\|CY\|GVAX	Phase II	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA	NCT03006302	Recruiting
Cyclophosphamide\|GVAX\|pembrolizumab\|radiation: SBRT	Phase II	The Sidney Kimmel Comprehensive Cancer at Johns Hopkins, Baltimore, Maryland, USA	NCT02648282	Ongoing
Cyclophosphamide\|GVAX\|pembrolizumab\|IMC-CS4	Early phase I	Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA	NCT03153410	Recruiting
CAR-T or TIL-based therapies
Activated CIK and CD3-MUC1 bispecific antibody in treating pancreatic cancer\|procedure: cryotherapy	Phase II	Institutional Review Board of Guangzhou Fuda Cancer Hospital, Guangzhou, Guangdong, China	NCT03509298	Ongoing
Anti-MUC1 CAR-pNK cells	Phase I Phase II	PersonGen BioTherapeutics (Suzhou) Co, Ltd, Suzhou, Jiangsu, China	NCT02839954	Unknown status
Anti-MUC1 CAR-T cells	Phase I Phase II	PersonGen Biomedicine (Suzhou) Co, Ltd, Suzhou, Jiangsu, China	NCT02587689	Unknown status
Anti-CEA CAR-T Cells\| gemcitabine/nab paclitaxel\| NLIR+FU/FA\|capecitabine	Phase II Phase III		NCT04037241	Not yet recruiting
multiTAA specific T cells	Phase I Phase II	Baylor Clinic, Houston, Texas, USA\|Houston Methodist Hospital, Houston, Texas, USA\|Harris Health System, Smith Clinic, Houston, Texas, USA	NCT03192462	Ongoing
BPX-601\|rimiducid	Phase I Phase II	Multicenter	NCT02744287	Ongoing
Young TIL\|aldesleukin\|cyclophosphamide\|fludarabine\|pembrolizumab (Keytruda)	Phase II	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, USA	NCT01174121	Ongoing
TEW-7197	Phase I Phase II	Samsung Medical Center, Seoul, Republic of Korea	NCT03666832	Ongoing
Pegylated recombinant human hyaluronidase PH20\|pembrolizumab	Phase II	M D Anderson Cancer Center, Houston, Texas, USA	NCT04058964	Not yet recruiting
Targetted small mlecule and antibody-based therapies in combination with ICI
Anti-SEMA4D monoclonal antibody VX15/2503\|ipilimumab\|nivolumab\|procedure: surgery	Phase I	Emory University, Atlanta, Georgia, USA	NCT03373188	Ongoing
APX005M\|nivolumab\|nab-paclitaxel\|gemcitabine	Phase I Phase II	Multicenter	NCT03214250	Active, not recruiting
XL888\|pembrolizumab	Phase I	Emory University, Atlanta, Georgia, USA	NCT03095781	Recruiting
Pembrolizumab\|defactinib	Phase II	Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA	NCT03727880	Ongoing
Antibiotics and pembrolizumab	Phase IV	NYU Langone Health, New York, New York, USA	NCT03891979	Not yet recruiting
ENB003 plus pembrolizumab phase Ib/IIa in solid tumors			NCT04205227
ENB003\|pembrolizumab	Phase I Phase II		NCT04205227	Not yet recruiting
GB1275\|nab-paclitaxel and gemcitabine\|pembrolizumab	Phase I Phase II	Multicenter	NCT04060342	Ongoing
Pembrolizumab\|sonidegib	Phase I	Mayo Clinic in Arizona, Scottsdale, Arizona, United States\|Mayo Clinic in Florida, Jacksonville, Florida, United States\|Mayo Clinic, Rochester, Minnesota, USA	NCT04007744	Ongoing
XmAb22841\|pembrolizumab (Keytruda)	Phase I	Multicenter	NCT03849469	Ongoing
FT500\|nivolumab\|pembrolizumab\|atezolizumab\|cyclophosphamide\|fludarabine	Phase I	Multicenter	NCT03841110	Ongoing
PEGPH20\|pembrolizumab	Phase II	Multicenter	NCT03634332	Ongoing
CPI-006\| CPI-006+ciforadenant\|CPI-006+pembrolizumab	Phase I	Multicenter	NCT03454451	Ongoing
Pembrolizumab\|paricalcitol\|placebo	Phase II	Multicenter	NCT03331562	Active, not recruiting
INT230-6\|anti-PD-1 antibody\|anti-CTLA-4 antibody	Phase I Phase II	Multicenter	NCT03058289	Ongoing
CXCR4 Antagonist BL-8040\| Pembrolizumab\|Other: Pharmacological Study	Phase II	M D Anderson Cancer Center, Houston, Texas, USA	NCT02907099	Active, not recruiting
Adoptive immunotherapy\|aldesleukin\|cyclophosphamide\|other: laboratory biomarker analysis\| pembrolizumab	Phase I	M D Anderson Cancer Center, Houston, Texas, USA	NCT02757391	Active, not recruiting
Pembrolizumab\|itacitinib\|INCB050465	Phase I	Multicenter	NCT02646748	Active, not recruiting
Pegilodecakin\|paclitaxel or docetaxel and carboplatin or cisplatin\|FOLFOX (oxaliplatin/leucovorin/5-fluorouracil)\|gemcitabine/nab-paclitaxel\|capecitabine\|pazopanib\|pembrolizumab\|paclitaxel\|nivolumab\| gemcitabine/carboplatin	Phase I	Multicenter	NCT02009449	Active, not recruiting
Nivolumab\|ipilimumab\|tocilizumab\|radiation: SBRT	Phase II	Herlev & Gentofte University Hospital, Denmark, Herlev, Denmark	NCT04258150	Ongoing
BT5528\|nivolumab	Phase I Phase II	Multicenter	NCT04180371	Ongoing
KRAS peptide vaccine\|nivolumab\|ipilimumab	Phase I	Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA	NCT04117087	Not yet recruiting
Nivolumab\|radiation: radiation therapy\|TLR9 agonist SD-101	Phase I	University of California Davis Comprehensive Cancer Center, Sacramento, California, USA	NCT04050085	Ongoing
Part 1 TPST-1120\|part 2a TPST-1120+nivolumab\|part 2b TPST-1120+docetaxel\|part 2c TPST-1120+cetuximab\|part 3 TPST-1120\|part 4a TPST-1120+nivolumab\|part 4b TPST-1120+docetaxel\|part 4c TPST-1120+cetuximab	Phase I	Multicenter	NCT03829436	Ongoing
Anetumab ravtansine\|gemcitabine hydrochloride\|ipilimumab\|nivolumab	Phase I Phase II	Multicenter	NCT03816358	Ongoing
Nivolumab\|tadalafil\|oral vancomycin	Phase II	National Institutes of Health Clinical Center, Bethesda, Maryland, USA	NCT03785210	Ongoing
Radiation: SBRT\|nivolumab\|CCR2/CCR5 dual antagonist\|GVAX	Phase I Phase II	Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA	NCT03767582	Ongoing
FOLFIRINOX\|losartan\|nivolumab\|radiation: SBRT\|procedure: surgery	Phase II	Multicenter	NCT03563248	Ongoing
Niraparib+nivolumab\|niraparib+ipilimumab	Phase I Phase II	University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA	NCT03404960	Ongoing
Cabiralizumab\|nab-paclitaxel\|onivyde\|nivolumab\|fluorouracil\|gemcitabine\|oxaliplatin\|leucovorin\| irinotecan hydrochloride	Phase II	Multicenter	NCT03336216	Active, not recruiting
Nivolumab\|daratumumab	Phase I Phase II	Multicenter	NCT03098550	Active, not recruiting
FPA008\|BMS-936558	Phase I	Multicenter	NCT02526017	Active, not recruiting
BMS-813160\|nivolumab\|ab-paclitaxel\|gemcitabine\|5-fluorouracil\|leucovorin\|irinotecan	Phase I Phase II	Multicenter	NCT03184870	Ongoing

CAR-T, chimeric antigen receptor-expressing T cell; CCR2, chemokine receptor 2; ICI, immune checkpoint inhibition; PD-1, programmed cell death protein 1; PDAC, pancreatic ductal adenocarcinoma; SBRT, stereotactic body radiation; TIL, tumor-infiltrating lymphocyte.